Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. It develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. As of July 25, 2025, Ikena Oncology, Inc. was acquired by Inmagene Biopharmaceuticals Co. Ltd. Show more
Location: 645 Summer Street, Boston, MA, 02210, United States | Website: https://ikenaoncology.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
718.8M
52 Wk Range
$1.36 - $23.28
Previous Close
$14.74
Open
$14.54
Volume
6,821
Day Range
$14.00 - $14.73
Enterprise Value
-20.96M
Cash
95.64M
Avg Qtr Burn
-7.296M
Insider Ownership
8.00%
Institutional Own.
76.21%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
IK-175 (AHR Inhibitor) Details Bladder cancer, Solid tumor/s, Cancer, Urothelial carcinoma | Phase 1b Update | |
IK-595 (MEK-RAF Molecular Glue) Details Cancer, Solid tumor/s | Phase 1 Data readout | |
IK-930 (TEAD1) Details Cancer, Solid tumor/s, Non-small cell lung carcinoma | Failed Discontinued | |
IK-007 Details Solid tumor/s, Colorectal cancer , Cancer | Failed Discontinued |